Month: March 2011

Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference

CRANBURY, N.J., March 9, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011, at 12:00 p.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, …

Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference Read More »

FDA Clears Palatin Technologies’ IND Filing to Commence Clinical Studies for Asthma

CRANBURY, N.J., March 3, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Food and Drug Administration (FDA) has cleared Palatin’s request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug (IND) application using a subcutaneously administered formulation of PL-3994, an NPR-A agonist compound, in development …

FDA Clears Palatin Technologies’ IND Filing to Commence Clinical Studies for Asthma Read More »

Palatin Technologies, Inc. Closes $23 Million Public Offering

CRANBURY, N.J., March 1, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it has completed its previously announced public offering of 23,000,000 units, consisting of 23,000,000 shares of its common stock, Series A Warrants to purchase 2,000,000 shares of its common stock and Series B Warrants to purchase 21,000,000 shares of …

Palatin Technologies, Inc. Closes $23 Million Public Offering Read More »

Scroll to Top